201 related articles for article (PubMed ID: 37350807)
1. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
[TBL] [Abstract][Full Text] [Related]
2. Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.
Newsome RC; Gharaibeh RZ; Pierce CM; da Silva WV; Paul S; Hogue SR; Yu Q; Antonia S; Conejo-Garcia JR; Robinson LA; Jobin C
Genome Med; 2022 Mar; 14(1):35. PubMed ID: 35346337
[TBL] [Abstract][Full Text] [Related]
3. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
4. The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors.
Wu Z; Zhang S; Li L; Huang Z; Huang D; Hu Y
Front Oncol; 2022; 12():887383. PubMed ID: 36387171
[TBL] [Abstract][Full Text] [Related]
5. The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti-Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC.
Jin Y; Dong H; Xia L; Yang Y; Zhu Y; Shen Y; Zheng H; Yao C; Wang Y; Lu S
J Thorac Oncol; 2019 Aug; 14(8):1378-1389. PubMed ID: 31026576
[TBL] [Abstract][Full Text] [Related]
6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
7. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
Oh B; Boyle F; Pavlakis N; Clarke S; Eade T; Hruby G; Lamoury G; Carroll S; Morgia M; Kneebone A; Stevens M; Liu W; Corless B; Molloy M; Kong B; Libermann T; Rosenthal D; Back M
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638308
[No Abstract] [Full Text] [Related]
8. The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Shimamoto T; Iwasaku M; Kaneko Y; Uchino J; Takayama K
Transl Lung Cancer Res; 2019 Dec; 8(6):847-853. PubMed ID: 32010563
[TBL] [Abstract][Full Text] [Related]
9. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
[TBL] [Abstract][Full Text] [Related]
10. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer.
Peng Z; Cheng S; Kou Y; Wang Z; Jin R; Hu H; Zhang X; Gong JF; Li J; Lu M; Wang X; Zhou J; Lu Z; Zhang Q; Tzeng DTW; Bi D; Tan Y; Shen L
Cancer Immunol Res; 2020 Oct; 8(10):1251-1261. PubMed ID: 32855157
[TBL] [Abstract][Full Text] [Related]
11. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non-small-cell lung cancer patients.
Zhang C; Wang J; Sun Z; Cao Y; Mu Z; Ji X
Cancer Sci; 2021 Aug; 112(8):3005-3017. PubMed ID: 34028936
[TBL] [Abstract][Full Text] [Related]
12. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
13. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer.
Shoji F; Yamaguchi M; Okamoto M; Takamori S; Yamazaki K; Okamoto T; Maehara Y
Front Mol Biosci; 2022; 9():1040424. PubMed ID: 36353732
[TBL] [Abstract][Full Text] [Related]
15. Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota.
He D; Li X; An R; Wang L; Wang Y; Zheng S; Chen X; Wang X
Oncol Ther; 2021 Dec; 9(2):647-657. PubMed ID: 34664203
[TBL] [Abstract][Full Text] [Related]
16. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
19. Dual Biomarker Combining DNA Damage Repair Gene Mutations and PD-L1 Expression for Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Kim H; Lim DH; Kwon YS; Kim MA; Park KU
Anticancer Res; 2023 May; 43(5):2343-2349. PubMed ID: 37097676
[TBL] [Abstract][Full Text] [Related]
20. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
